| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
The name of the plan is the Lisata Therapeutics, Inc. 2026 Equity Incentive Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultan... |
| 14 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee |
| 17 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of September 17, 2026, by and among Lisata Therapeutics, Inc., a Delaware corporation (“Parent”), Mariner Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiar... |
| 04 Aug 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
We are pleased to inform you that, in recognition of your contributions to Lisata Therapeutics, Inc. (the “Company”), you are being offered the opportunity to receive a retention bonus (the “Retention Bonus”) on the following terms and c... |
| 24 Jul 2026 |
8-K: Termination of a Material Definitive Agreement; Other Events
On July 24, 2026, Lisata Therapeutics, Inc. (the “Company”) terminated the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Kuva Labs Inc., a Delaware corporation (“Parent”) and Kuva Acquisition ... |
| 17 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated July 16, 2026, is made by and among, Kuva Labs Inc., a Delaware corporation (“Parent”), Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary... |
| 09 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT AND WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated June 8, 2026, is made by and among, Kuva Labs Inc., a Delaware corporation (“Parent”), Kuva Acquisition Corp., a Delaware corporation and a wholly owned sub... |
| 01 Jun 2026 |
8-K: Other Events
As previously announced, on May 29, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsid... |
| 29 May 2026 |
8-K: Entry into a Material Definitive Agreement
This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], 2026 (this “Agreement”), is entered into by and between Kuva Labs Inc., a Delaware corporation (“Parent”), and Equiniti Trust Company, LLC, a New York limited liability trust compa... |
| 04 May 2026 |
8-K: Entry into a Material Definitive Agreement
This AMENDMENT AND WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated May 3, 2026, is made by and among, Kuva Labs Inc., a Delaware corporation (“Parent”), Kuva Acquisition Corp., a Delaware corporation and a wholly owned subs... |
| 15 Apr 2026 |
8-K: Other Events
As previously disclosed, on April 2, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsi... |
| 03 Apr 2026 |
8-K: Other Events
This WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated April 2, 2026, is made by and among, Kuva Labs Inc., a Delaware corporation (“Parent”), Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Pa... |
| 09 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among KUVA LABS INC., KUVA ACQUISITION CORP. and LISATA THERAPEUTICS, INC. Dated as of March 6, 2026 |
| 27 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
AMENDMENT TO BINDING TERM SHEET This Amendment to Binding Term Sheet (“Amendment”) is made effective as of February 27, 2026, by and between Kuva Labs Inc., a Delaware corporation (“Kuva”) and Lisata Therapeutics, Inc., a Delaware corpor... |
| 27 Jan 2026 |
8-K: Other Events
On January 23, 2026, Lisata Therapeutics, Inc. (the “Company”) and Qilu Pharmaceutical Co., Ltd. (“Qilu”) entered into a Mutual Termination Agreement (the “Termination Agreement”) relating to the Exclusive License and Collaboration Agree... |
| 21 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
#100810477v16 Exhibit 2.1 BINDING TERM SHEET This Binding Term Sheet (the “Term Sheet”) constitutes a commitment by the parties hereto to negotiate in good faith and to enter into one or more definitive agreements as set forth herein. Th... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | November 6, 2025 Nasdaq: LSTA Exhibit 99.2 |
| 14 Oct 2025 |
8-K: Regulation FD Disclosure
© L i s a t a T h e r a p e u t i c s , I n c . 2 0 2 5 . A l l r i g h t s r e s e r v e d . Targeted Therapy Delivered www.lisata.com Corporate Presentation | October 14, 2025 Nasdaq: LSTA Exhibit 99.1 |
| 08 Oct 2025 |
8-K: Entry into a Material Definitive Agreement
On October 8, 2025, Lisata Therapeutics, Inc. (the “Company”) entered into a worldwide Non-Exclusive License Agreement (the “Non-Exclusive License Agreement” or the “Agreement”) with Catalent, Inc. (“Catalent”), pursuant to which the Com... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone |
Loading...